阅读说明：本技术 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 (Combination of an IL-4/IL-13 pathway inhibitor and plasma cell ablation for the treatment of allergy ) 是由 S·阿斯拉特 A·利曼德 J·奥伦戈 G·D·扬科普洛斯 A·J·墨菲 于 2020-03-20 设计创作，主要内容包括：本申请提供了治疗过敏症的方法,该方法包含选择具有过敏症的患者并且施用治疗有效量的IL-4/IL-13途径抑制剂(例如抗-IL-4受体抗体或其抗原结合片段)与治疗有效量的耗尽浆细胞的活性剂(例如抗-BCMA/抗-CD3双特异性抗体)的组合。在某些实施方案中,浆细胞消融剂例如抗-BCMA/抗-CD3双特异性抗体消融了浆细胞,包括IgE+浆细胞,而IL-4/IL-13途径抑制剂防止新的IgE+浆细胞生成,由此消除患者的变应原特异性IgE。(The present application provides methods of treating allergy comprising selecting a patient with allergy and administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of a plasma cell depleting active agent (e.g., an anti-BCMA/anti-CD 3 bispecific antibody). In certain embodiments, the plasma cell ablator, e.g., an anti-BCMA/anti-CD 3 bispecific antibody, ablates plasma cells, including IgE + plasma cells, while the IL-4/IL-13 pathway inhibitor prevents the production of new IgE + plasma cells, thereby eliminating allergen-specific IgE in the patient.)